Nexavar(R) Approved By European Commission For The Treatment Of Advanced Kidney Cancer

Mon, 24 Jul 2006 11:00 AM EST

... BayerPharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc.(Nasdaq: ONXX) today announced that the European Commission has grantedmarketing authorization to Nexavar(R) (sorafenib) tablets for the treatmentof patients with advanced renal cell carcinoma who have failed priorinterferon- alpha or interleukin-2 based therapy or are consideredunsuitable for such therapy. [click link for full article] ...